Opsens – 100,000 Cases Performed with the OptoWire
20 May 2020Opsens – 100,000 cases performed with the OptoWire Quebec City, Quebec, May 20, 2020 – OpSens Inc. (“OpSens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF) reached an important milestone with more than 100,000 patients evaluated with the OptoWire™, a pressure guidewire for the diagnosis and treatment of coronary artery stenosis. Accuracy in assessing the severity of coronary disease…
OpSens at C-Suite at the Open
27 April 2020TORONTO, April 27, 2020 /CNW/ The C-Suite At the Open video interview series highlights the unique perspectives of listed companies on Toronto Stock Exchange and TSX Venture Exchange. Videos provide insight into how company executives think in the current business environment. To see the latest C-Suite At The Open videos visit http://www.newswire.ca/en/releases/archive/April2020/27/c0533.html. About OpSens Inc. (TSX:OPS) OpSens focuses mainly…
OpSens Announces Q2 2020 Results
9 April 2020OPSENS ANNOUNCES Q2 2020 RESULTS Quebec City, Quebec, April 9, 2020 – OpSens Inc. (“OpSens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF) today reported its results for the second quarter of 2020. Highlights OpSens continues operations and adjusts to face the COVID-19 crisis; Consolidated product sales totaled $8.3 M in the second quarter of 2020 compared with…
OPSENS PROVIDES OPERATIONAL UPDATE – Continues to supply essential cardiovascular solutions to patients around the world
24 March 2020OPSENS PROVIDES OPERATIONAL UPDATE Continues to supply essential cardiovascular solutions to patients around the world Quebec City, Quebec, March 24, 2020 – OpSens Inc. (“OpSens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF), a cardiology-focused company delivering diagnostic and treatment solutions based on its proprietary optical technology, today provided a business update in light of recent action taken…
OPSENS RECEIVES dPR CLEARANCE FROM FDA
19 December 2019Opsens Receives dPR Clearance from the FDA Product approval will bolster U.S. commercial efforts Quebec City, Quebec, December 19, 2019 – Opsens Inc. (“Opsens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF) announces 510(k) clearance from the U.S. Food and Drug Administration (“FDA”) to market its diastolic pressure algorithm (“dPR”). Coronary physiology has been in constant evolution with…
OPSENS – RECORD FY2019 CONSOLIDATED REVENUES OF $32.8 M, UP 36%, RECORD FFR REVENUES OF $20 M, UP 41%
14 November 2019OPSENS – RECORD FY2019 CONSOLIDATED REVENUES OF $32.8 M, UP 36%, RECORD FFR REVENUES OF $20 M, UP 41% Quebec City, Quebec, November 14, 2019 – Opsens Inc. (“Opsens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF) today reported its results for 2019. Highlights FOR THE QUARTER AND FOR THE YEAR Record consolidated revenues at $32.8 M for…
OPSENS ANNOUNCES ENTRY INTO STRUCTURAL HEART MARKET
5 November 2019OPSENS ANNOUNCES ENTRY INTO STRUCTURAL HEART MARKET Expands core technology into fastest growing segment of cardiology devices Quebec City, Quebec, November 5, 2019 – Opsens Inc. (“Opsens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF) announces today it is expanding its medical device business into the structural cardiology space and will accelerate development activities of products that reach…
Opsens Solutions will be present at ESREF 2019
29 August 2019We are going to be happy to meet you at booth 6 – ESREF 2019 – the 30th European Symposium on Reliability of Electron Devices, Failure Physics and Analysis – September 23-26, 2019, at Centre de Congrès Pierre Baudis, Toulouse, France.
OPSENS SOLUTIONS – STRATEGIC ORDER FOR FIBER OPTIC SENSORS TO BE DEPLOYED IN NEW INDUSTRIAL DEWATERING PROCESS
16 July 2019Quebec City, Quebec, July 16, 2019 – Opsens Inc. (“Opsens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF) today announced that Opsens Solutions Inc. (“Opsens Solutions”), its wholly-owned subsidiary, has received an order for more than a hundred fiber optic sensors and systems, to be deployed in a new dewatering process of oil sands tailings. The order…
OPSENS – Q3 2019 – RECORD QUARTERLY FFR REVENUES OF $5.2 M, UP 49%
11 July 2019Quebec City, Quebec, July 11, 2019 – Opsens Inc. (“Opsens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF) today reported its results for the third quarter of 2019. Highlights Consolidated revenues of $7.9 M for the third quarter of 2019 compared with $6.4 M for the third quarter of 2018, an increase of $1.5 M or 23%; Fractional…